相似文献
1
Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin.
Aliment Pharmacol Ther. 2008 Aug 1;28(3):289-93. doi: 10.1111/j.1365-2036.2008.03718.x.
2
Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients.
AIDS Behav. 2013 Jan;17(1):94-103. doi: 10.1007/s10461-012-0288-9.
3
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Antivir Ther. 2011;16(6):833-41. doi: 10.3851/IMP1837.
4
IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.
J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.
5
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
AIDS. 2006 May 12;20(8):1157-61. doi: 10.1097/01.aids.0000226956.02719.fd.
6
Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
Clin Infect Dis. 2012 Sep;55(5):728-36. doi: 10.1093/cid/cis500. Epub 2012 May 18.
7
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
J Antimicrob Chemother. 2007 Dec;60(6):1347-54. doi: 10.1093/jac/dkm373. Epub 2007 Oct 14.
8
Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.
Aliment Pharmacol Ther. 2009 Jul;30(1):14-27. doi: 10.1111/j.1365-2036.2009.04004.x. Epub 2009 Mar 26.
9
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
AIDS. 2011 May 15;25(8):1025-33. doi: 10.1097/QAD.0b013e3283471cae.
10
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3.
引用本文的文献
1
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3.
2
New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo.
J Manag Care Spec Pharm. 2015 Sep;21(9):S1-14. doi: 10.18553/jmcp.2015.21.9.S1.
3
Self-efficacy and adherence to antiviral treatment for chronic hepatitis C.
J Clin Gastroenterol. 2015 Jan;49(1):76-83. doi: 10.1097/MCG.0000000000000055.
4
Impact of hepatitis C treatment initiation on adherence to concomitant medications.
J Assoc Nurses AIDS Care. 2014 Jan-Feb;25(1):23-31. doi: 10.1016/j.jana.2013.07.004. Epub 2013 Sep 24.
5
Adherence to chronic hepatitis C treatment regimen: first report from a referral center in iran.
Hepat Mon. 2013 Jun 23;13(6):e11038. doi: 10.5812/hepatmon.11038. eCollection 2013.
6
Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence.
J Viral Hepat. 2013 Aug;20(8):536-49. doi: 10.1111/jvh.12079. Epub 2013 Feb 25.
7
Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients.
AIDS Behav. 2013 Jan;17(1):94-103. doi: 10.1007/s10461-012-0288-9.
8
Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?
J Consult Clin Psychol. 2013 Apr;81(2):361-74. doi: 10.1037/a0029030. Epub 2012 Jun 25.
9
Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients.
AIDS Res Treat. 2011;2011:903480. doi: 10.1155/2011/903480. Epub 2011 Oct 26.
10
Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.
Ann Intern Med. 2011 Sep 20;155(6):353-60. doi: 10.7326/0003-4819-155-6-201109200-00003.
本文引用的文献
1
Limited uptake of hepatitis C treatment among injection drug users.
J Community Health. 2008 Jun;33(3):126-33. doi: 10.1007/s10900-007-9083-3.
2
HIV and liver disease forum: conference proceedings.
Hepatology. 2007 Jun;45(6):1566-77. doi: 10.1002/hep.21722.
3
Assessing the validity of self-reported medication adherence in hepatitis C treatment.
Ann Pharmacother. 2007 Jul;41(7):1116-23. doi: 10.1345/aph.1K024. Epub 2007 May 22.
4
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.
AIDS. 2007 May 31;21(9):1073-89. doi: 10.1097/QAD.0b013e3281084e4d.
5
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Gastroenterology. 2007 Jan;132(1):103-12. doi: 10.1053/j.gastro.2006.11.011. Epub 2006 Nov 11.
6
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
AIDS Care. 2007 Jan;19(1):138-45. doi: 10.1080/09540120600645539.
7
Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care.
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S349-54. doi: 10.1086/427452.
8
Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin.
J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):238-40. doi: 10.1097/01.qai.0000148535.97081.72.
9
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
JAMA. 2004 Dec 15;292(23):2839-48. doi: 10.1001/jama.292.23.2839.
10
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
N Engl J Med. 2004 Jul 29;351(5):451-9. doi: 10.1056/NEJMoa032653.
Zotero 插件